June 23, 2014 Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
June 19, 2014 Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
May 28, 2014 Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
May 14, 2014 Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men’s and Women’s Cancers at 2014 ASCO Annual Meeting
May 14, 2014 Capricor Therapeutics to Hold First Quarter 2014 Business Update Conference Call on May 15, 2014 at 4:30 p.m. Eastern Time
May 6, 2014 Capricor Therapeutics Enters Into Exclusive License With Cedars-Sinai Medical Center for Exosome-Related IP Portfolio
April 11, 2014 Kite Pharma Expands Company’s Board of Directors with the Appointment of Jonathan M. Peacock
April 7, 2014 Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer
April 2, 2014 Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer
April 1, 2014 Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
March 31, 2014 Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product
March 28, 2014 Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
March 26, 2014 Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
March 4, 2014 Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
January 21, 2014 Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
